UNITED STATES
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (date of earliest event reported): May 14,
2020
GENETHERA, INC.
(Exact name
of registrant as specified in its charter)
|
Nevada
|
000-27237
|
65-0622463
|
|
(State
or other jurisdiction of
|
(Commission
|
(IRS
Employer
|
|
incorporation or
organization)
|
File
Number)
|
Identification
No.)
|
|
3051 W.
105th
Ave., Unit 350251
|
|
|
Westminster,
CO
|
80031
|
|
(Address of
principal executive offices)
|
(Zip
code)
|
Registrant’s
telephone number, including area
code:
(720)
587-5100
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (Section
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (Section 240.12b-2 of this chapter).
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
1
ITEM
8.01—OTHER EVENTS
GeneThera Inc. (the “Company”) will be relying on the
Securities and Exchange Commission’s Order under Release No.
34-88465 (the ”Order”) to delay the filing of its
Annual Report on Form 10-K for the year ended December 31, 2019 due
to circumstances related to COVID-19. In particular, the
predecessor auditor has not provided access to all their workpapers
to our successor auditor due to the ‘stay-at-home’
working environments, which has caused extra procedures to be
performed by the successor auditor. The Company intends to rely on
the Form 12b-25 to further extend the filing deadline of Form
10-K.
The Company will be including additional disclosures in the Form
10-K regarding the uncertainty of future operations due to
COVID-19. It will also include disclosures on how the
Company’s technology may be used in a positive manner in the
fight against the COVID-19 pandemic.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GeneThera inc.
|
|
|
|
|
|
|
|
|
Dated: May 15,
2020
|
By:
|
/s/ Tannya L.
Irizarry
|
|
|
|
|
Chief Financial
Officer (Interim)
|
|
2